(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -5.9% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Amarin's revenue in 2026 is $213,646,000.On average, 4 Wall Street analysts forecast AMRN's revenue for 2026 to be $74,012,158,313, with the lowest AMRN revenue forecast at $65,320,264,974, and the highest AMRN revenue forecast at $82,396,153,084. On average, 4 Wall Street analysts forecast AMRN's revenue for 2027 to be $74,944,175,597, with the lowest AMRN revenue forecast at $60,256,581,779, and the highest AMRN revenue forecast at $89,735,789,202.
In 2028, AMRN is forecast to generate $73,720,902,911 in revenue, with the lowest revenue forecast at $57,169,274,523 and the highest revenue forecast at $90,522,178,786.